Alex Nemiroff
General Counsel bei PRAXIS PRECISION MEDICINES, INC.
Vermögen: 192 640 $ am 31.03.2024
Profil
Alex Nemiroff is the founder and Chief Executive Officer of RogCon, Inc., which was founded in 2015.
He is also the founder and Chief Executive Officer of RogCon U.R., Inc., which is also founded in 2015.
Currently, Mr. Nemiroff holds the position of Secretary & General Counsel at Praxis Precision Medicines, Inc. since 2020.
In terms of education, Mr. Nemiroff has an undergraduate degree from Stephen M.
Ross School of Business and a graduate degree from Northwestern University School of Law.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 12.02.2024 | 3 157 ( 0,02% ) | 192 640 $ | 31.03.2024 |
Aktive Positionen von Alex Nemiroff
| Unternehmen | Position | Beginn |
|---|---|---|
| PRAXIS PRECISION MEDICINES, INC. | General Counsel | 01.01.2020 |
RogCon, Inc.
 RogCon, Inc. Pharmaceuticals: MajorHealth Technology RogCon, Inc. engages in the discovery and development of novel treatments for SCN2A mutations that cause epilepsy, autism and other neurological disorders. The company was founded by Kelley Dalby, Steven Petrou and Alex Nemiroff and is headquartered in Miami Beach, FL. | Chief Executive Officer | 01.11.2015 |
| RogCon U.R., Inc. | Chief Executive Officer | 01.11.2015 |
Ausbildung von Alex Nemiroff
| Stephen M. Ross School of Business | Undergraduate Degree |
| Northwestern University School of Law | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| PRAXIS PRECISION MEDICINES, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
RogCon, Inc.
RogCon, Inc. Pharmaceuticals: MajorHealth Technology RogCon, Inc. engages in the discovery and development of novel treatments for SCN2A mutations that cause epilepsy, autism and other neurological disorders. The company was founded by Kelley Dalby, Steven Petrou and Alex Nemiroff and is headquartered in Miami Beach, FL. | Health Technology |
| RogCon U.R., Inc. |
